Overview QA102 Phase II Study in Subjects With Dry AMD Status: Not yet recruiting Trial end date: 2025-10-01 Target enrollment: Participant gender: Summary This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of GA or CNV in high-risk eyes. Phase: Phase 2 Details Lead Sponsor: Smilebiotek Zhuhai Limited